Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan

Pool, James L.; Schmieder, Roland E.; Azizi, Michel; Aldigier, Jean-Claude; Januszewicz, Andrzej; Zidek, Walter; Chiang, Yann Tong; Satlin, Andrew

doi:10.1016/j.amjhyper.2006.06.003

Cited by 197 publications

(189 citation statements)

References 23 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…Direct inhibition of renin with aliskerin has been shown to have beneficial effects on blood pressure, inflammation, fibrosis, and end-organ damage (155,243,256,333). A recent study, Aliskiren in the EValuation of PrOteinuria In Diabetes (AVOID) Trial, showed that the addition of a renin inhibitor to an ARB in diabetic and hypertensive patients decreases proteinuria further when compared with an ARB alone (251).…”

Section: B Role Of the Raas In Oxidative Stress And Hypertensionmentioning

confidence: 99%

Redox Control of Renal Function and Hypertension

Nistala

Whaley‐Connell

Sowers

2008

Antioxidants & Redox Signaling

136

123

View full text Add to dashboard Cite

Section: B Role Of the Raas In Oxidative Stress And Hypertensionmentioning

confidence: 99%

Redox Control of Renal Function and Hypertension

Nistala

Whaley‐Connell

Sowers

2008

Antioxidants & Redox Signaling

136

123

View full text Add to dashboard Cite

“…14,15,[17][18][19][20][21][22] Data were analysed for aliskiren 150 mg and 300 mg (the US Food and Drug Administration and European Union approved doses for the treatment of hypertension) and placebo after 8 or 12 weeks of treatment for the subgroups of women and men. All of the trials were 8 weeks in duration, except for the aliskiren vs ramipril (6 months) and aliskiren vs HCT (12 months) studies.…”

Section: Methodsmentioning

confidence: 99%

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies

et al. 2010

View full text Add to dashboard Cite

Hypertension is a major risk factor for cardiovascular disease, which is the leading cause of mortality in women in developed countries. This pooled analysis assessed the antihypertensive efficacy, safety and tolerability of monotherapy with the direct renin inhibitor aliskiren (150 mg and 300 mg) over 8-12 weeks in women with mild-to-moderate hypertension (mean sitting diastolic blood pressure (msDBP)X95 and o110 mm Hg) across eight randomized and double-blind trials. Safety and tolerability were assessed in the five placebo-controlled trials in the analysis. In the 1527 women enrolled in these studies, aliskiren 150 mg and 300 mg produced significantly greater blood pressure (BP) reductions (14.1/11.0 and 16.1/12.3 mm Hg, respectively) compared with placebo (7.2/7.6 mm Hg; Po0.0001). BP reductions with aliskiren monotherapy in women were similar to those observed in men, and consistent across subgroups of age, metabolic syndrome and obesity. The overall incidence of adverse events in women was similar with aliskiren treatment (150 mg, 42.3%; 300 mg, 46.0%) and placebo (39.0%); adverse events with aliskiren were more frequent in women than in men, consistent with previous studies of gender differences in drug tolerability. In conclusion, aliskiren monotherapy at 150 mg and 300 mg doses provided effective, dose-dependent BP-lowering in women with mild-to-moderate hypertension, and it was well tolerated.

show abstract

“…41 An increased incidence of diarrhea (9.5%) was observed at a dose of 600 mg in comparison to a placebo (1.2%). The total number of reported adverse events was similar to those with a placebo.…”

Section: Safetymentioning

confidence: 95%

Hypertension Management and End Organ Protection: Focus on Aliskiren

Imanishi

Tsujioka

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Abstract:The renin-angiotensin system (RAS) activity is a key factor in the pathophysiology and development of hypertension, atherosclerosis, heart failure, and renal disease. It is unclear whether angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) have fully delivered the expected reductions in cardiovascular risk. In fact, the optimized RAS suppression is diffi cult to achieve with these agents, partly because ACE inhibitors and ARBs both activate compensatory feedback mechanisms that result in renin release and increase plasma renin activity (PRA). Molecular modeling was used to develop aliskiren, a potent, low-molecular-weight, nonpeptide, direct renin inhibitor with suffi cient bioavailability to produce sustained suppression of PRA after oral administration. This report discusses the mechanisms of action of oral renin inhibitors and their pharmacokinetic properties. In addition, the report also evaluates the available data regarding the effects of the renin inhibitor aliskiren in the treatment of hypertension and related cardiovascular disorders.

show abstract

Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan

Abstract: Aliskiren monotherapy provides antihypertensive efficacy and placebo-like tolerability in patients with hypertension. Aliskiren and valsartan in combination may provide additive BP-lowering effects with maintained tolerability.

Cited by 197 publications

References 23 publications

Redox Control of Renal Function and Hypertension

Redox Control of Renal Function and Hypertension

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies

Hypertension Management and End Organ Protection: Focus on Aliskiren

Contact Info

Product

Resources

About